Should Guardant Health’s (GH) Role in ENHERTU’s Japan Approval Require Action From Investors?

Guardant Health’s InfinityAI platform was instrumental in obtaining Japan’s approval for Daiichi Sankyo’s ENHERTU, showcasing its potential in leveraging clinicogenomic data and AI for regulatory assessments. While this strengthens Guardant’s position in the biopharma and data sectors, the article emphasizes that the core investment risks remain centered on high spending, negative free cash flow, and potential future dilution. Investors should consider the company’s long-term financial health and growth forecasts despite this positive development in real-world evidence.